Publications

5808 Results

Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial PMID20833684

Authors
RT Chlebowski;R Menon;RM Chaisanguanthum;DM Jackson
Journal / Conference
Clinical Trials 7(6):744-748
Year
2010
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Obesity is an independent prognostic variable in colon cancer survivors [PMID20215553; PMC2948494]

Authors
F Sinicrope;NR Foster;DJ Sargent;MJ O'Connell;C Rankin
Journal / Conference
Clinical Cancer Research 16(6):1884-1893
Year
2010
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)

Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer

Authors
JA Sparano;M Wang;S Martino;V Jones;EA Perez;T Saphner;AC Wolff;GW Sledge;W Wood;J Fetting;NE Davidson
Journal / Conference
San Antonio Breast Cancer Symposium, abst. #S2-1; poster
Year
2010
Research Committee(s)
Breast
Study Number(s)
E1199

c-MYC (MYC) protein expression and associations iwth trastuzumab benefit in early-stage, HER2+ breast cancer in context of the NCCTG adjuvant trial, N9831

Authors
MM Reinholz;AC Dueck;AE Wiktor;WL Lingle;RB Jenkins;NE Jenkins;S Martino;PA Kaufman;LA Kutteh;G Sledge;LN Harris;JR Gralow;X Geiger;EA Perez
Journal / Conference
San Antonio Breast Cancer Symposium, abst. #P2-09-08; poster
Year
2010
Research Committee(s)
Breast
Study Number(s)
N9831

Quantitative protein and gene expression biomarkers of tamoxifen and letrozole recurrence in the NCIC CTG MA.17 cohort

Authors
DC Sgroi;DM Finkelstein;L Shepherd;JN Ingle;DL Rimm;H Sassano;P Porter;M Pins;S Paik;A Ristimaki;K Pritchard;D Tu;PE Goss
Journal / Conference
San Antoino Breast Cancer Symposium, abst. #p3-10-26; poster
Year
2010
Research Committee(s)
Breast
Study Number(s)
JMA17

Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in post-menopausal women with hormone receptor positive primary breast cancer

Authors
PE Goss;JN Ingle;MJ Ellis;G Sledge;GT Budd;M Ragaglio;K Gelmon;L Shepherd;KI Pritchard
Journal / Conference
San Antonio Breast Cancer Symposium, #S1-1; poster
Year
2010
Research Committee(s)
Breast

Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers

Authors
J Harbison;D Horak;S Maier;TJ Lynch;D Gandara;KJ O'Byrne;R Pirker;M Weber;S Khambata-Ford
Journal / Conference
Journal of Clinical Oncology 28:15s (suppl; abstr 7548); ASCO annual meeting; poster
Year
2010
Research Committee(s)
Lung
Study Number(s)
S0342, S0536

KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424

Authors
PC Mack;M Redman;K Chansky;S Matsumoto;W Holland;P Lara;C Ambrosone;DR Gandara
Journal / Conference
Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 7013); ASCO annual meeting; poster
Year
2010
Research Committee(s)
Lung
Study Number(s)
S0424

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19

Authors
GD Goss;I Lorimer;MS Tsao;CJ O'Callaghan;K Ding;GA Masters;D Gandara;JR Jett;MJ Edelman;FA Shepherd
Journal / Conference
Journal of Clinical Oncology 28:18s, 2010 (suppl; abstr LBA7005); ASCO annual meeting; poster
Year
2010
Research Committee(s)
Lung

A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC)

Authors
D Karp;J Lee;L Shaw Wright;DH Johnson;MR Johnston;GE Goodman;GH Clamon;GS Okawara;R Marks;J Ruckdeschel
Journal / Conference
Journal of Clinical Oncology 28:18s, 2010 (suppl; abstr CRA7004); ASCO Annual Meeting; oral
Year
2010
Research Committee(s)
Lung
Study Number(s)
E5597